Pfizer signs $1.25bn cancer antibody licensing deal with China's 3SBio

The US giant will pay the money upfront for distribution rights for SSGJ-707 outside of China; the deal could be worth up to $4.8bn and Pfizer will also invest $100m into the HKEX listed firm.
May 21, 2025

Pfizer has entered into an exclusive global, ex-China, licensing agreement with 3SBio a Chinese biopharmaceutical company, listed on the Hong Kong Stock Exchange HKEX, according to a May 19 company announcement. 

The agreement is for the development, manufacturing and commercialisation of SSGJ-707, a bispecific antibody targeting PD-1 programmes cell death proterin 1 and VEGF vascular endothelial growth factor. 

SSGJ-707 has shown initial efficacy and safety data in a promising class of cancer medicines, Pfizer said in a media release. 3SBio plans to initiate the first Phase 3 study in China in 2025. It is undergoing several clinical trials in...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222